In recent years, the incidence rate of lung cancer has been increasing year by year. Lung cancer originates from the epithelium of bronchial mucosa and may grow into the bronchial lumen or adjacent lung tissues, and may spread through lymphatic hematogenous or transbronchial metastasis. Lung cancer is one of the most dangerous malignant tumors to human health in the world, and more than 1.6 million people die of lung cancer every year, mainly due to brain metastasis. The most common treatments for lung cancer are surgery, chemotherapy and radiotherapy, while radiotherapy is often rejected due to its many side effects. In recent years, stereotactic radiotherapy (SABR) has been a hot research topic, and stereotactic radiotherapy can reduce or even avoid these side effects. According to the literature, stereotactic radiotherapy can not only protect the normal brain tissues around the tumor well, but also give large dose irradiation to the lesion, which can effectively improve the therapeutic gain coefficient, reduce the complications, improve the therapeutic efficacy, and it is uniquely superior in the treatment of brain metastases. EDGE is by far the most advanced, precise and effective stereotactic radiotherapy technology, using the unique FDA approved Calypso GPS for the Body system and surface beam monitoring system approved by the FDA on July 21, 2014 to monitor and lock the tumor “escape” in the process of treatment at a high frequency of up to 10 milliseconds in real time dynamically, combined with the new generation of IGRT and other image-guiding technologies. Combined with the new generation of IGRT and other image-guidance technologies, the unique high-intensity HD-MLC collimator of up to 2,400 MU/min removes tumor tissue with sub-millimeter precision and almost no residue. EDGE tumor non-invasive surgical removal system has the following advantages compared with conventional surgery and conventional chemotherapy: 1. Non-invasive: no incision is required, patients do not need to undergo the huge trauma of surgery; 2. Short treatment time: about 10 minutes of treatment time each time, which does not affect the quality of life of patients; 3. Fewer treatments: 1-5 treatments once a day, no need to be hospitalized; 4. Highly efficient: it can simultaneously remove up to 5 Tumor, resection of tumor can be up to 5-7cm, almost suitable for all solid tumor patients for lesion removal; 5, Thorough: tracking and locking the escaped tumor and removing it at a frequency of every 10 milliseconds to eliminate tumor cells completely; 6, High-intensity precision treatment: high energy, 0,2 millimeter level precision to eliminate tumor cells, almost no damage to the surrounding vital organs and tissues; 7, Convenient: no need for anesthesia, no need for hospitalization; 8, Almost no side effects: patients do not have the side effects of conventional surgery and radiotherapy. It has been reported that the research groups in the United States and the Netherlands, treated 58 non-small cell lung cancer patients suitable for surgery in randomized groups, 31 patients with stereotactic radiotherapy and 27 patients with surgery, and the results showed that the 3-year overall survival rate, 95% in the radiotherapy group, was significantly better than that of 79% in the surgery group. This also indicates that the therapeutic effect of adopting radiation therapy for early stage non-small cell lung cancer (NSCLC) is better than that of surgery. According to the experts of Global Oncologist Network, EDGE is the most advanced non-invasive tumor removal technology so far, which can treat benign or malignant solid tumors at any site, especially tumors near vital organs or major blood vessels and nerves, and it has excellent therapeutic effect on tumors that are difficult to be performed by conventional surgery, such as cranial tumors, lung cancers, breast cancers, spinal tumors, liver cancers and other solid tumors.